➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Medtronic
Harvard Business School
Express Scripts

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,765,053


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,765,053 protect, and when does it expire?

Patent 9,765,053 protects NUPLAZID and is included in two NDAs.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 9,765,053
Title:Methods of treatment using selective 5-HT2A inverse agonists
Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Inventor(s): Andersson; Carl-Magnus A. (Glostrup, DK), Croston; Glenn (San Diego, CA), Hansen; Eva Louise (Glostrup, DK), Uldam; Allan Kjaersgaard (Glostrup, DK)
Assignee: ACADIA Pharmaceuticals Inc. (San Diego, CA)
Application Number:13/053,079
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,765,053

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acadia Pharms Inc NUPLAZID pimavanserin tartrate CAPSULE;ORAL 210793-001 Jun 28, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS ⤷  Free Forever Trial
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS ⤷  Free Forever Trial
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,765,053

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 348808 ⤷  Free Forever Trial
Australia 2005202257 ⤷  Free Forever Trial
Australia 4007201 ⤷  Free Forever Trial
Australia 780006 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKinsey
Baxter
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.